Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $54.00 at Robert W. Baird

Karyopharm Therapeutics (NASDAQ:KPTI) had its target price cut by Robert W. Baird from $75.00 to $54.00 in a research report report published on Monday morning,Benzinga reports. They currently have an outperform rating on the stock.

Other equities research analysts have also recently issued reports about the company. Piper Sandler upped their price target on Karyopharm Therapeutics from $60.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. StockNews.com cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 price target on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. Finally, HC Wainwright increased their target price on Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $57.50.

Karyopharm Therapeutics Stock Performance

KPTI opened at $7.25 on Monday. Karyopharm Therapeutics has a 52-week low of $7.14 and a 52-week high of $25.50. The stock has a market capitalization of $61.05 million, a PE ratio of -7.11 and a beta of 0.06. The stock’s 50 day moving average price is $9.81 and its 200-day moving average price is $11.24.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, topping the consensus estimate of ($3.90) by $0.30. The firm had revenue of $30.54 million during the quarter, compared to analysts’ expectations of $30.29 million. Research analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of KPTI. GSA Capital Partners LLP lifted its holdings in shares of Karyopharm Therapeutics by 80.6% during the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock valued at $1,474,000 after purchasing an additional 792,283 shares in the last quarter. FMR LLC lifted its holdings in shares of Karyopharm Therapeutics by 26.1% during the third quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after purchasing an additional 76,510 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Karyopharm Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock valued at $1,125,000 after purchasing an additional 43,856 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Karyopharm Therapeutics by 15.3% during the fourth quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock valued at $1,633,000 after purchasing an additional 319,187 shares in the last quarter. Finally, TD Waterhouse Canada Inc. bought a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at $32,000. 66.44% of the stock is owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).